ADAR1 Capital Management »

Relmada Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Relmada Therapeutics (RLMD) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Relmada Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Relmada Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Relmada Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $2.8k 601 4.65
2023-12-31 $243k 59k 4.14

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Relmada Therapeutics

Franklin Resources
Vanguard Group
Deep Track Capital
Acadian Asset Management
Parsons Capital Management
Palo Alto Investors
BlackRock
BlackRock
Vestal Point Capital
Opaleye Management
Jpmorgan Chase & Co
Geode Capital Management
Two Sigma Advisers
Deutsche Bank Aktiengesellschaft
Bank of America Corporation

View all funds holding Relmada Therapeutics